Use of the cathelicidin LL-37 and derivatives therof for wound healing
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 6, 2011
Grant Date -
Apr 2, 2009
app pub date -
Sep 12, 2008
filing date -
Jan 29, 2003
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully